ClinicalTrials.gg
RecruitingNCT07026539FineCaReUpdated Jun 24, 2025

Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.

A Phase 4 interventional study of Finerenone (BAY 94-8862) and Placebo in Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease Due to Type 2 Diabetes Mellitus and Cardiovascular Diseases, sponsored by University of Aarhus. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Oct 2024, registered Jun 2025).
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing finerenone in Diabetes Mellitus, Type 2 — 5 open to participants now, 6 under way, none of them phase 3. finerenone · Diabetes Mellitus, Type 2.

Planned enrollment
11th of 13
80 · median 100
Started
2024
with 3 others
Phase 4
7 of 13
4 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
University of Aarhus

Among the 13 studies testing finerenone in Diabetes Mellitus, Type 2, this one is the 11th largest by planned enrollment, is one of 4 that started in 2024, is one of 7 in phase 4, and was the 11th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 13 studies testing finerenone in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing finerenone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The global prevalence of diabetes is increasing substantially. Around 40 % of patients with type 2 diabetes develop chronic kidney disease. Diabetic kidney disease is the leading cause of kidney failure, it is closely linked to cardiovascular disease and heart failure and is associated with a threefold increase in all-cause mortality and a 16-year loss in life expectancy.

In large clinical trials, the novel drug finerenone has shown to lower the risk of chronic kidney disease progression and improve the cardiovascular outcome for patients with type 2 diabetes and chronic kidney disease. However these trials did not not reflect current standard-of-care for patients with type 2 diabetes and chronic kidney disease, as only a minority (6.7 %) received an SGLT2-I - a treatment that has been considered standard-of-care for these patients since 2022.

The FineCaRe study aims to investigate the effect of treatment with finerenone in combination with an SGLT2-I on albuminuria and left ventricular mass in patients with type 2 diabetes and chronic kidney disease.

The investigators will perform a 26-week investigator-initiated, single-center, placebo-controlled, double-blinded randomized clinical trial. After screening and inclusion, participants will be randomized 1:1 to either finerenone or placebo treatment. Outcomes will be assessed at baseline, during and after 26 weeks of treatment.

The primary goal of the FineCaRe study is to acquire new knowledge that may help in preventing kidney failure in diabetic patients. With this project the investigators aim to contribute to the understanding of which disease mechanisms in the kidneys and heart that can be targeted in diabetic patients with kidney disease. This could hopefully provide better opportunities for preventing chronic kidney disease and kidney failure.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Chronic Kidney Disease Due to Type 2 Diabetes Mellitus
  • Cardiovascular Diseases

Keywords

  • Mineralocorticoid receptor antagonist (MRA)
  • Type 2 diabetes
  • Chronic kidney disease
  • Diabetic complications
  • finerenone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 18 years.
  • Diagnosis of type 2 diabetes according to the World Health Organization definition.
  • Current treatment with a SGLT2-I1 at maximally tolerated dose.
  • Current treatment with an ACE inhibitor or an ARB1 at maximally tolerated dose.
  • Plasma potassium level of 4.8 mmol/L or less at the time of screening.
  • CKD defined as ≥25 ml/min/1.73 m2 and albuminuria (UACR between 30-5000 mg/g).
  • Speak and understand Danish fluently.

Exclusion criteria

Exclusion Criteria:

  • Inability to give .
  • Severe renal disease with \<25 ml/min/1.73m2.
  • Severe hepatic disease (plasma ALAT above 3 x ).
  • Active cancer diagnosis other than basal cell carcinoma.
  • Treatment with systemic at time of randomization.
  • Bariatric surgery within 2 years or other gastrointestinal surgeries that induce chronic malabsorption.
  • Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake.
  • Chronic or acute pancreatitis.
  • Pregnancy or breastfeeding (see pregnancy below).
  • Poorly controlled medical condition, e.g. congestive heart failure ( III-IV or EF ≤ 40%), recent (within 3 months) stroke or acute myocardial infarction or any other condition that in the opinion of the investigator will put the trial participant at risk if participating in the trial.
  • Allergy to finerenone or any of the contained in the drug.
  • Current systemic treatment with strong inhibitors of (e.g. itraconazol, ketoconazole, ritonavir, cobicistat, clarithromycin) or strong inducers of CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital).
  • Current treatment with other MRAs (e.g. spironolactone, eplerenone etc.).
  • Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose- galactose malabsorption.
  • Addison's disease.
  • to MRI.
  • Previous renal or heart transplantation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Finerenone (active)

    Drug: Finerenone (BAY 94-8862)

Interventions

  • DrugFinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients with an eGFR of 25-60 ml/min/1.73m2 will receive an initial dose of 10 mg finerenone/placebo once daily and those with an eGFR of at least 60 ml/ in/1.73m2 will receive an initial dose of 20 mg finerenone/placebo once daily. From 4 weeks the target dose is 20 mg finerenone/placebo once daily. An increase in dose from 10 to 20 mg once daily will be encouraged after 4 weeks provided the plasma potassium level is 4.8 mmol/L or less and the eGFR stable. If eGFR is reduced with \>30 % compared to the previous measurement, we will not increase the dose of finerenone/placebo. Plasma potassium and eGFR will be measured 4 weeks after any initiation, re-start or increase in dose. A decrease in dose from 20 to 10 mg is allowed at any time after initiation of finerenone or placebo. Patients in the placebo group will undergo sham adjustment of the dose. Finerenone or placebo will be withheld if potassium concentrations exceed 5.5 mmol/L and restarted if potassium levels fall to 5.0 mmol/L

  • DrugPlacebo

    Placebo tablets matching BAY94-8862 are administered orally.

06

What researchers measure

Primary outcomes

  1. Change in left ventricular mass measured by non-contrast cardiac MRI of the heart

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  2. Change in albuminuria measured by a urinary albumin-to-creatinine ratio (UACR) in morning spot urine samples (first morning voids).

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

Secondary outcomes

  1. Change in the rate of myocardial fibrosis (extracellular cardiac volume - ECV %) measured by MRI of the heart using gadolinium-containing contrast.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  2. Change in the rate of myocardial fibrosis measured by non-contrast T1-mapping using MRI of the heart.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  3. Change in left ventricular ejection fraction (EF), left ventricular and atrial volumes measured by non-contrast MRI of the heart.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  4. Change in thoracic aortic wall volume (TWV) measured by MRI of the heart.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  5. Change in the rate of pulse wave velocity in the aorta measured by non-contrast MRI of the heart.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  6. Change in arterial stiffness assessed as cf-PWV.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  7. Change in 24-hour blood pressure.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  8. Change in inflammatory and fibrotic biomarkers related to CVD measured in blood and urine.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  9. Change in measured glomerular filtration rate (mGFR) assessed by injection of a tracer.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  10. Change in eGFR slope including all available outpatient eGFR measured a) from before treatment to last day of treatment b) from 4 weeks after treatment initiation to last day after treatment.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  11. Change in UACR by repeated measures analysis including all available outpatient UACR measurements from before treatment to the last day after treatment.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  12. Change in markers of the RAAS measured in blood and urine.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  13. Change in inflammatory and fibrotic biomarkers related to CKD (e.g. markers of renal tubule damage) measured in blood and urine.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  14. Change in kidney microstructure and fibrosis assessed as changes in T1-mapping and changes in the rate of ADC-values of diffusion-weighted MRI of the kidneys using non-contrast MRI.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  15. Change in renal oxygenation assessed by BOLD MRI and change in renal perfusion with a pseudo continuous arterial spin labeling (pCASL), both non-contrast MR techniques

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  16. Change in kidney size measured by a Dixon water/fat sequence MRI, a non-contrast MRI technique.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

Other outcomes

  1. Change in retinal thickness assessed with Optical Coherence Tomography (OCT).

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  2. Change in retinal oxygenation measured by oximetry.

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

  3. Change in the transcriptomic, proteomic, and/or metabolomic profile in plasma and urine. Furthermore, to test if possible changes can be related to pathways involved in and/or serve as biomarkers of the progression of cardiovascular and/or kidney disease

    Time frame: From the baseline visit at week 0 to the end of treatment at week 26.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated during the described study will not be publicly available due to privacy and ethical restrictions. Interested parties can request access to deidentified data or anonymised study reports by submitting a request to the primary investigator, provided that the necessary data protection agency and ethical committee approvals are given, in compliance with relevant legislation.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 26 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Jun 18, 2025
StartActual
Oct 23, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Apr 30, 2028
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07026539
Responsible party
Sponsor
First posted
Jun 18, 2025
Start date
Oct 23, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Jun 24, 2025

Study contacts

Lene Halkjær, MD
Contact
lene.halkjaer@clin.au.dk
+4528928399
Per L Poulsen, Professor
Contact
perpouls@rm.dk

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion